Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 21, 2023
Deals
July 20 Quick Takes: Via its second preclinical deal this week, Sanofi gains Recludix’s oral STAT6 inhibitor
Plus: Idorsia sells Japan, Korea business to Sosei and updates from Gossamer and BioNTech-Biotheus
BioCentury | Mar 18, 2023
Finance
March 17 Quick Takes: Digital play Pear seeking alternatives
Plus: Gossamer pauses brain-penetrant Btk program, and updates from Pfizer, Astellas, Novartis and more
BioCentury | Oct 11, 2022
Product Development
PAH treatment moves in a disease-modifying direction with Merck data
Sotatercept meets primary and most secondary endpoints in Phase III pulmonary arterial hypertension study
BioCentury | Jul 13, 2022
Data Byte
Gossamer gets lift from $120M private placement with crossovers
With milestones looming, biotech extends runway into mid-2024
BioCentury | Apr 26, 2022
Product Development
April 25 Quick Takes: Gossamer’s IBD therapy fails Phase II trial
Plus Black Diamond discontinues program and updates from AstraZeneca, Axsome, Eliem, Roche and more
BioCentury | Apr 20, 2022
Data Byte
The Phase III pipeline for ovarian cancer
Companies are testing 15 therapies across four mechanisms; five trials to report data this year
BioCentury | Feb 22, 2021
Management Tracks
Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore
Israeli diagnostics company Novellus has tapped former Immunomedics executive Usama Malik as its new CEO as it moves to the U.S. and rebrands as a precision therapeutics company, the newly named Fore
BioCentury | Mar 10, 2020
Product Development
March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi
BioCentury | Jan 25, 2020
Emerging Company Profile
Aluda: targeting the fundamentals
Aluda begins to unveil pipeline, starting with first-in-class anti-VIM program for fibrosis
BioCentury | Dec 16, 2019
Clinical News
Novartis’ asthma failure weighs on Gossamer’s shares ahead of readout
Items per page:
1 - 10 of 183